US 11,987,624 B2
Human monocarboxylate transporter 1 antibodies and uses thereof
Frank Charles Dorsey, Indianapolis, IN (US); Joseph Benjamin Granger, Indianapolis, IN (US); Kira Vladimirovna Rubtsova, San Diego, CA (US); Oliver Schroeder, Encinitas, CA (US); and Wei Wang, Zionsville, IN (US)
Assigned to lmmunometabolism Development Company, LLC, Indianapolis, IN (US)
Filed by Immunometabolism Development Company, LLC, Indianapolis, IN (US)
Filed on Sep. 14, 2022, as Appl. No. 17/932,039.
Claims priority of provisional application 63/272,903, filed on Oct. 28, 2021.
Claims priority of provisional application 63/261,177, filed on Sep. 14, 2021.
Prior Publication US 2023/0111363 A1, Apr. 13, 2023
Int. Cl. C07K 16/28 (2006.01); A61P 37/00 (2006.01); C12N 15/85 (2006.01)
CPC C07K 16/28 (2013.01) [A61P 37/00 (2018.01); C12N 15/85 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 34 Claims
 
1. An antibody or antigen binding fragment thereof that specifically binds human MCT1, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and the VL comprises light chain complementarity determining regions LCDR1, LCDR2, and LCDR3, wherein:
a. the HCDR1 comprises SEQ ID NO: 30;
the HCDR2 comprises SEQ ID NO: 31;
the HCDR3 comprises SEQ ID NO: 32;
the LCDR1 comprises SEQ ID NO: 33;
the LCDR2 comprises SEQ ID NO: 5; and
the LCDR3 comprises SEQ ID NO: 6;
b. the HCDR1 comprises SEQ ID NO: 30;
the HCDR2 comprises SEQ ID NO: 2;
the HCDR3 comprises SEQ ID NO: 56, SEQ ID NO: 64, SEQ ID NO: 68, or SEQ ID NO: 72;
the LCDR1 comprises SEQ ID NO: 33;
the LCDR2 comprises SEQ ID NO: 5; and
the LCDR3 comprises SEQ ID NO: 6;
c. the HCDR1 comprises SEQ ID NO: 30;
the HCDR2 comprises SEQ ID NO: 2;
the HCDR3 comprises SEQ ID NO: 99;
the LCDR1 comprises SEQ ID NO: 33;
the LCDR2 comprises SEQ ID NO: 5; and
the LCDR3 comprises SEQ ID NO: 6;
d. the HCDR1 comprises SEQ ID NO: 30;
the HCDR2 comprises SEQ ID NO: 2;
the HCDR3 comprises SEQ ID NO: 72;
the LCDR1 comprises SEQ ID NO: 4;
the LCDR2 comprises SEQ ID NO: 5; and
the LCDR3 comprises SEQ ID NO: 6;
e. the HCDR1 comprises SEQ ID NO: 30;
the HCDR2 comprises SEQ ID NO: 2;
the HCDR3 comprises SEQ ID NO: 68;
the LCDR1 comprises SEQ ID NO: 4;
the LCDR2 comprises SEQ ID NO: 5; and
the LCDR3 comprises SEQ ID NO: 6;
f. the HCDR1 comprises SEQ ID NO: 40, SEQ ID NO: 48, SEQ ID NO: 52, SEQ ID NO: 60, SEQ ID NO: 76, SEQ ID NO: 80 or SEQ ID NO: 84;
the HCDR2 comprises SEQ ID NO: 2;
the HCDR3 comprises SEQ ID NO: 32;
the LCDR1 comprises SEQ ID NO: 33;
the LCDR2 comprises SEQ ID NO: 5; and
the LCDR3 comprises SEQ ID NO: 6;
g. the HCDR1 comprises SEQ ID NO: 97;
the HCDR2 comprises SEQ ID NO: 2;
the HCDR3 comprises SEQ ID NO: 32;
the LCDR1 comprises SEQ ID NO: 33;
the LCDR2 comprises SEQ ID NO: 5; and
the LCDR3 comprises SEQ ID NO: 6;
h. the HCDR1 comprises SEQ ID NO: 30;
the HCDR2 comprises SEQ ID NO: 44 or SEQ ID NO: 88;
the HCDR3 comprises SEQ ID NO: 32;
the LCDR1 comprises SEQ ID NO: 33;
the LCDR2 comprises SEQ ID NO: 5; and
the LCDR3 comprises SEQ ID NO: 6; or
i. the HCDR1 comprises SEQ ID NO: 30;
the HCDR2 comprises SEQ ID NO: 98;
the HCDR3 comprises SEQ ID NO: 32;
the LCDR1 comprises SEQ ID NO: 33;
the LCDR2 comprises SEQ ID NO: 5; and
the LCDR3 comprises SEQ ID NO: 6.